Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 16.3% during trading on Thursday . The stock traded as high as C$0.28 and last traded at C$0.25. 610,571 shares were traded during trading, a decline of 2% from the average session volume of 621,060 shares. The stock had previously closed at C$0.22.
Hemostemix Price Performance
The stock has a market capitalization of C$27.01 million, a PE ratio of -15.50 and a beta of 0.20. The firm’s 50 day simple moving average is C$0.11 and its 200 day simple moving average is C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- Stock Market Sectors: What Are They and How Many Are There?
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- Pros And Cons Of Monthly Dividend Stocks
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
